EpimAb, Innovent Announce Collaboration
News Jun 25, 2016
EpimAb Biotherapeutics and Innovent Biologics have announced a multiple target agreement for the development of bispecific antibodies. Under the terms of the agreement, Innovent will gain access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform to develop multiple bispecific antibodies for the Chinese market, including the right to out-license the developed programs outside of China.
In return for commercialization rights to these molecules in China, EpimAb is eligible to receive an upfront payment and total milestones of up to $120 MM, plus royalties. In the event Innovent licenses the rights of the developed candidates outside of China, EpimAb will receive an undisclosed share of the net receipts. Further details of the terms were not disclosed.
“We are very pleased to have gained Innovent as our first licensee,” said Dr. Chengbin Wu, CEO and founder of EpimAb. “Innovent’s world class R&D and biologics CMC capabilities are perfectly suited to develop novel FIT-Ig® bispecific antibodies. We believe that our proprietary FIT-Ig® bispecific antibodies technology is a unique approach to the bispecifics space. Together with multiple partners, we will increase the variety of FIT-Ig® molecules and advance them through the clinic to create novel treatments for severe human diseases.”
The innovative FIT-Ig® technology offers a novel approach for generating bispecific antibodies, whereby the bispecifics fully retain the biological properties of their parental monoclonal antibodies without the need to significantly modify the basic structural elements of the bispecific antibody. FIT-Ig® molecules generated to date have demonstrated not only excellent biological and pharmacological characteristics, but also great physical-chemical properties.
“We are delighted to work with EpimAb as their first partner for this exciting technology. We have known Dr. Chengbin Wu for a long time and think that the FIT-Ig® technology will fit nicely in our bispecific discovery platform,” said Michael Yu, Chief Executive Officer and Co-Founder of Innovent. “In addition to the bispecific deal that Innovent entered into with Eli Lilly and Company last year, this will allow us to further expand our efforts.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019